NewAmsterdam Pharma Company N.V (NAMS) Stock Price & How to Invest

Last updated November 2026

Short answer

NAMS is NewAmsterdam Pharma, a late-stage biopharma whose value rests almost entirely on obicetrapib, an oral CETP inhibitor for lowering LDL cholesterol. The drug won its first approval anywhere in September 2026, when the European Commission cleared it (as Ubeslo and Evlarco, marketed by partner Menarini), but the shares closed at $19.04 on November 20, 2026, down about 46% this year, as attention shifted to a PREVAIL outcomes-trial interim the company now expects to read out in the first quarter of 2027. Investing in it means underwriting a single cardiovascular drug, funded by a ~$643 million cash pile against ongoing losses.

NAMS stock price

As of 2026-11-20, NewAmsterdam Pharma Company N.V (NAMS) last closed at $18.41, down 51.9% over the past year. Over the past 52 weeks it has traded between $18.41 and $41.45.

NAMS last close
$18.41
1 day
-5.64%
1 month
-14.33%
1 year
-51.89%
52-week range
$18.41 to $41.45
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or NewAmsterdam Pharma Company N.V's investor relations page. Walnut is informational, not investment advice.

NAMS key stats

At $18.41 on November 20, 2026, NewAmsterdam Pharma Company N.V (NAMS) has a market cap of $2.2B.

Market cap
$2.2B
Price to book
3.5
Beta
0.14

Market cap, P/E and yield are measured at the $18.41 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with NewAmsterdam Pharma Company N.V (NAMS)?

The last two weeks for NewAmsterdam Pharma Company N.V, as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • NAMS closed at $18.41 on November 20, 2026, down 8.6% over the past five trading days (from $20.14).
  • On November 11, 2026, Cantor Fitzgerald raised its target to $61.00 from $52.00 (Overweight).

NewAmsterdam Pharma Company N.V filed no current, quarterly or annual report with the SEC in the last two weeks.

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

What does NewAmsterdam Pharma Company N.V (NAMS) do?

NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company headquartered in Naarden, the Netherlands, and listed on Nasdaq under the ticker NAMS. Its lead candidate is obicetrapib, an oral, once-daily, low-dose CETP inhibitor being developed as a non-statin option (alone or as a fixed-dose combination with ezetimibe) to lower LDL cholesterol in patients who are not reaching targets on existing therapy. The company reported positive topline data from registrational Phase 3 trials including BROADWAY, BROOKLYN and TANDEM, and is running the large PREVAIL cardiovascular outcomes trial; European rights are partnered with the Menarini Group, and on September 21, 2026 the European Commission approved obicetrapib as Ubeslo (10 mg monotherapy) and Evlarco (with 10 mg ezetimibe) for primary hypercholesterolaemia, the drug's first approval worldwide. A Phase 2b trial called SPINOZA, which dosed its first participant in September 2026, now tests obicetrapib in preclinical Alzheimer's disease, building on an earlier Phase 2a program.

The investment picture is a classic late-stage biotech setup. In the third quarter of 2026, reported November 4, revenue jumped to about $19.2 million from $0.3 million a year earlier, driven by regulatory milestones under the Menarini license, and the net loss narrowed to about $17.4 million from $72.0 million, helped by a $23.1 million non-cash gain on warrants; R&D spending rose to $39.4 million. Yahoo Finance records EPS of roughly -$0.12, compared with a consensus near -$0.44. Cash, equivalents and marketable securities were about $643.1 million against negligible debt, giving it a multi-year runway to fund trials and a potential US launch. Under the Menarini deal it earns tiered royalties on European sales, from the low double digits to the mid-twenties in percentage terms, and is eligible for up to EUR 817 million more in milestones; Menarini plans to launch in Germany by the end of 2026 and in the UK in 2027. The market capitalization has fallen to about $2.3 billion at $19.04 a share on November 20, 2026, down about 30% over three months and about 50% over one year. The company expects PREVAIL to reach its predefined event number for the interim analysis in the fourth quarter of 2026, with results in the first quarter of 2027, and topline data from the RUBENS Phase 3 trial around year-end. RBC in early October put the odds of a positive PREVAIL interim at only 35% to 38% because of the risk of too few cardiovascular events at that look, while seeing better odds at the final analysis by the end of 2027. The stock behaves like an option on that outcomes readout and on US regulatory progress rather than on current financials.

What's driving NewAmsterdam Pharma Company N.V (NAMS)?

1. Obicetrapib approval path

Obicetrapib has posted positive registrational Phase 3 data (LDL-C reductions of roughly 33% as monotherapy and about 49% combined with ezetimibe in reported studies). That data produced the first approval in September 2026, when the European Commission cleared Ubeslo and Evlarco for primary hypercholesterolaemia. A US approval as an oral, non-statin add-on would open a large addressable population of statin-treated patients who remain above LDL targets, and the US path is the bigger prize for NewAmsterdam because Europe is Menarini's to sell.

2. Oral, once-daily convenience versus injectables

The competitive pitch is a pill rather than an injection. Leading potent LDL-lowering drugs such as PCSK9 inhibitors are injectables, so an effective oral option could appeal to patients and prescribers who prefer a tablet, potentially widening use in primary care.

3. Deep cash runway and Menarini partnership

About $643 million in cash, equivalents and marketable securities (as of September 30, 2026) funds the ongoing PREVAIL outcomes trial and launch preparation without immediate financing pressure, down from about $729 million at the end of 2025. The Menarini Group partnership provides European commercialization reach and non-dilutive economics: milestones lifted third-quarter revenue to about $19.2 million, and NewAmsterdam keeps tiered royalties from the low double digits to the mid-twenties plus up to EUR 817 million in further milestones as Menarini launches in Germany by year-end 2026 and the UK in 2027.

4. Cardiovascular outcomes optionality

The PREVAIL cardiovascular outcomes trial could, if positive, extend the label from LDL lowering to demonstrated event reduction, which historically drives payer coverage and broader adoption. A favorable outcomes readout would be the single largest potential value inflection. PREVAIL completed enrollment in April 2024 with more than 9,500 patients. The company expects to hit the interim event count in the fourth quarter of 2026 and report results in the first quarter of 2027. RBC rates that interim the largest near-term catalyst, but estimates only a 35% to 38% chance of success at the interim, versus higher odds at the final analysis by end-2027.

What are the risks to NewAmsterdam Pharma Company N.V (NAMS)?

The company is still essentially pre-revenue, with about $26 million of trailing revenue, much of it one-time Menarini milestones, against a trailing net loss of about $205 million, so the valuation depends on obicetrapib being approved in the US and commercially adopted; a regulatory setback or a disappointing PREVAIL outcomes result would remove much of the thesis. The near-term risk is sharper now: RBC's statistical work puts the chance of a positive PREVAIL interim in early 2027 at 35% to 38%, and an interim that falls short would at minimum push the outcomes story out to the final analysis. CETP inhibitors as a class have a difficult history, with several prior candidates from large pharma failing in outcomes trials, which keeps skepticism elevated. Concentration is extreme because essentially all value sits in one molecule. Ongoing losses mean future capital raises and shareholder dilution are possible despite the current cash cushion of about $643 million. Commercial risk is real even after approval, given entrenched generics, injectable PCSK9 competitors, and payer access hurdles, and the stock's roughly 46% drop in 2026 shows how quickly sentiment can move. Third-quarter revenue also flattered the run rate: analysts expect only about $1.2 million of revenue in the first quarter of 2027 once milestone payments fall away, and the narrower Q3 loss leaned on a non-cash warrant gain.

What is the NewAmsterdam Pharma Company N.V (NAMS) forecast?

14 analysts publish price targets on NAMS, averaging $50.80 as of November 2026, or +175.9% against the $18.41 share price on November 20, 2026. The published targets run from $37.44 to $60.09, a moderate spread, and the ratings split 15 buy, 1 hold, 0 sell. Over the last six months there have been 2 raises and 3 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full NAMS forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is NAMS a buy or a sell?

We give no verdict on NewAmsterdam Pharma Company N.V. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Obicetrapib approval path. Obicetrapib has posted positive registrational Phase 3 data (LDL-C reductions of roughly 33% as monotherapy and about 49% combined with ezetimibe in reported studies). The most optimistic published target, $60.09, assumes this works close to its best case.

The case against. The company is still essentially pre-revenue, with about $26 million of trailing revenue, much of it one-time Menarini milestones, against a trailing net loss of about $205 million, so the valuation depends on obicetrapib being approved in the US and commercially adopted; a regulatory setback or a disappointing PREVAIL outcomes result would remove much of the thesis. The most pessimistic target, $37.44, is roughly what NAMS is worth if this bites instead.

Read the full bull and bear case on NAMS, including what would have to change to break either one. Walnut is not an investment adviser.

Has NewAmsterdam Pharma Company N.V (NAMS) split its stock?

No. NewAmsterdam Pharma Company N.V (NAMS) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is NewAmsterdam Pharma Company N.V (NAMS) valued?

Market cap, P/E and dividend yield at today's price are in the NAMS key stats above. The business figures below come from NewAmsterdam Pharma Company N.V's reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~$26M; Q3 2026 ~$19.2M, mostly Menarini milestones
  • Net loss (TTM): ~$205M; Q3 2026 ~$17.4M (incl. ~$23.1M warrant gain)
  • Cash: ~$643M cash and securities, negligible debt

As of November 2026: The revenue base is small and lumpy, consisting mainly of milestone and supply income under the Menarini agreement, so traditional multiples are not meaningful. At about $2.3 billion, the market cap is roughly 3.5 times the cash balance, down from about $4.4 billion in May, as the EU approval was overshadowed by doubts about the PREVAIL interim. Analysts expect about $34.6 million of revenue in 2026 and $42.0 million in 2027, with losses continuing, and 14 analysts carry a mean target near $51.

Who competes with NewAmsterdam Pharma Company N.V (NAMS)?

Injectable PCSK9 inhibitors

Amgen's Repatha (evolocumab) and Novartis' Leqvio (inclisiran) are potent LDL-lowering injectables that can reduce LDL by roughly 50% or more on top of statins. They set the efficacy benchmark, though they require injection and can carry access and cost hurdles.

Oral non-statin lipid therapies

Esperion's Nexletol and Nexlizet (bempedoic acid, alone or with ezetimibe) plus generic ezetimibe are the closest oral competitors for patients not at target on statins. Obicetrapib would compete directly for this add-on oral niche.

Statins and emerging CETP or gene-based approaches

High-intensity generic statins remain the low-cost first-line standard, while newer approaches under study across the industry (other CETP programs, siRNA and gene-based lipid therapies) could reshape the dyslipidemia market over time.

What stocks are similar to NewAmsterdam Pharma Company N.V (NAMS)?

Other names that sit close to NAMS: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in NewAmsterdam Pharma Company N.V (NAMS)

There are three common ways to get NAMS exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so NAMS sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where NAMS fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on NewAmsterdam Pharma Company N.V (NAMS)

NAMS is a one-asset, early-commercial biopharma story: positive Phase 3 LDL data, a European approval, a first milestone-driven revenue quarter and a deep cash runway on one side, small recurring revenue and binary outcomes-trial and US regulatory risk on the other, with the PREVAIL interim result expected in early 2027.

More on NewAmsterdam Pharma Company N.V (NAMS)

Whether NAMS is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is NAMS a buy or a sell?, and where the stock could go from here in the NAMS stock forecast.

For income investors, whether NAMS pays a dividend and how the payout looks is covered in does NAMS pay a dividend? And to weigh NAMS against a peer, read the full side-by-side comparisons: NAMS vs AMGN and NAMS vs NVS.

Wondering how NAMS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about NewAmsterdam Pharma Company N.V

Ask Walnut's AI anything about NAMS and see how it fits what you own.

FAQ

What does NewAmsterdam Pharma (NAMS) do?

+

It is a late-stage biopharmaceutical company developing obicetrapib, an oral CETP inhibitor for lowering LDL cholesterol in patients with cardiovascular disease and inherited high-cholesterol conditions. The drug was approved in the European Union in September 2026, where partner Menarini sells it, but NewAmsterdam does not yet sell an approved drug at scale in the US.

What is obicetrapib?

+

Obicetrapib is an oral, once-daily, low-dose CETP inhibitor designed to lower LDL cholesterol, developed alone or as a fixed-dose combination with ezetimibe. In reported Phase 3 trials it lowered LDL-C by roughly 33% as monotherapy and about 49% in combination with ezetimibe. In Europe it is sold as Ubeslo (monotherapy) and Evlarco (with ezetimibe).

Is NAMS profitable?

+

No. In Q3 2026 revenue rose to about $19.2 million, mostly from Menarini milestones, but the company still posted a net loss of about $17.4 million, and that figure was helped by a $23.1 million non-cash warrant gain. The trailing net loss is about $205 million. Like most clinical-stage biopharma, it spends heavily on trials, and analysts expect losses to continue through 2027.

How much cash does NewAmsterdam have?

+

The company reported about $643.1 million in cash, cash equivalents and marketable securities as of September 30, 2026, with almost no debt, down from about $728.9 million at the end of 2025. That balance is meant to fund the PREVAIL outcomes trial and launch preparation, giving it a multi-year runway relative to its current burn rate.

Why is NAMS worth billions with almost no revenue?

+

Its market cap of about $2.3 billion (November 20, 2026) reflects investor expectations that obicetrapib will be widely used, not current sales. The figure has fallen from about $4.4 billion in May as concern grew about the PREVAIL interim, a reminder that the stock prices future commercial potential and is sensitive to trial and regulatory news.

Who are NAMS's main competitors?

+

Injectable PCSK9 inhibitors like Amgen's Repatha and Novartis' Leqvio, oral options such as Esperion's bempedoic acid products, and low-cost generic statins and ezetimibe. Obicetrapib would compete as an oral add-on for patients not at LDL target.

What are the biggest risks with NAMS?

+

The value is concentrated in one drug, so a regulatory rejection or a negative PREVAIL cardiovascular outcomes result would be severe. CETP inhibitors as a class have a history of trial failures, and ongoing losses could require future capital raises and dilution. RBC estimates only a 35% to 38% chance the PREVAIL interim, expected in early 2027, comes out positive.

What could move NAMS stock next?

+

The PREVAIL interim analysis is the largest near-term catalyst: the company expects to reach the predefined event count in the fourth quarter of 2026 and report results in the first quarter of 2027. Other events include RUBENS Phase 3 topline data around year-end 2026, Menarini's launch of Ubeslo and Evlarco in Germany by the end of 2026 and the UK in 2027, US regulatory progress, and the final PREVAIL analysis. Each is binary in nature, so the shares can be volatile around these events.

Is obicetrapib approved?

+

Yes, in the European Union. On September 21, 2026 the European Commission approved Ubeslo (obicetrapib 10 mg) and Evlarco (obicetrapib 10 mg plus ezetimibe 10 mg) for primary hypercholesterolaemia, the first approval of obicetrapib anywhere. Menarini handles European commercialization and pays NewAmsterdam tiered royalties. A US approval had not been announced as of November 2026, and the third-quarter update did not give a US filing date.

How has NAMS stock performed in 2026?

+

As of the November 20, 2026 close of $19.04, NAMS is down about 46% year to date and about 50% over one year, near the bottom of its 52-week range of $17.90 to $42.21. The slide steepened over the past three months (down about 30%) despite the EU approval, as analysts flagged risk around the PREVAIL interim, and the stock slipped another 3% in the month after the third-quarter report. Fourteen analysts carry an average target near $51.

How did NewAmsterdam do in its latest quarter?

+

In the third quarter of 2026, reported November 4, revenue was about $19.2 million versus $0.3 million a year earlier, driven by regulatory milestones under the Menarini license. The net loss narrowed to about $17.4 million from $72.0 million, partly because of a $23.1 million non-cash gain on warrants, and EPS as recorded by Yahoo Finance (about -$0.12) beat the roughly -$0.44 consensus. Cash and securities ended at about $643.1 million.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with NewAmsterdam Pharma Company N.V's investor relations page or your broker before making investment decisions.